{"DataElement":{"publicId":"3535903","version":"1","preferredName":"Second Line Treatment Bevacizumab Progressive Disease Occurrence Date","preferredDefinition":"Calendar date of disease progression for a patient on second line Bevacizumab therapy.","longName":"SEC_BEVA_PD_DT","context":"NCIP","contextVersion":"1","DataElementConcept":{"publicId":"3535798","version":"1","preferredName":"Second Line Treatment Bevacizumab Progressive Disease Occurrence","preferredDefinition":"The second preferred therapy for a particular condition, used after first-line treatment fails or if a person cannot tolerate first-line drugs._A monoclonal antibody that may prevent the growth of blood vessels from surrounding tissue to a solid tumor._Cancer that is growing, spreading, or getting worse._An instance of something happening, such as an event or incident._","longName":"SEC_BEVA_PD_OCC","context":"NCIP","contextVersion":"1","ObjectClass":{"publicId":"3535796","version":"1","preferredName":"Second Line Treatment Bevacizumab","preferredDefinition":"The second preferred therapy for a particular condition, used after first-line treatment fails or if a person cannot tolerate first-line drugs.\r\n:A monoclonal antibody that may prevent the growth of blood vessels from surrounding tissue to a solid tumor.","longName":"C54350:C2039","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Second-Line Therapy","conceptCode":"C54350","definition":"The second preferred therapy for a particular condition, used after first-line treatment fails or if a person cannot tolerate first-line drugs.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Bevacizumab","conceptCode":"C2039","definition":"A recombinant humanized monoclonal antibody directed against the vascular endothelial growth factor (VEGF), a pro-angiogenic cytokine.  Bevacizumab binds to VEGF and inhibits VEGF receptor binding, thereby preventing the growth and maintenance of tumor blood vessels.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C5BCD4E4-2161-955E-E040-BB89AD434B0E","latestVersionIndicator":"Yes","beginDate":"2012-07-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-07-26","modifiedBy":"ONEDATA","dateModified":"2012-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3535761","version":"1","preferredName":"Progressive Neoplastic Disease Occurrence","preferredDefinition":"Cancer that is growing, spreading, or getting worse.:Occurrence; an instance of something happening.","longName":"C8510:C25275","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Progressive Neoplastic Disease","conceptCode":"C8510","definition":"Cancer that is growing, spreading, or getting worse.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Occurrence","conceptCode":"C25275","definition":"An instance of something happening, such as an event or incident.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C5BB542C-1CB2-0AC1-E040-BB89AD433A0A","latestVersionIndicator":"Yes","beginDate":"2012-07-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-07-26","modifiedBy":"ONEDATA","dateModified":"2012-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C5BCD4E4-216F-955E-E040-BB89AD434B0E","latestVersionIndicator":"Yes","beginDate":"2012-07-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-07-26","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2017121","version":"1","preferredName":"CTMS Date","preferredDefinition":"Date as required for Clinical Trials Monitoring Service submissions.  Exchange format is YYYYMMDD.  Display format is DDMMMYYYY, with the month display the first three letters of each month (Jan, Feb, Mar, etc.).","longName":"CTMS_DT","context":"NCI Standards","contextVersion":"1","type":"Non-enumerated","dataType":"DATE","minLength":"4","maxLength":"8","minValue":null,"maxValue":null,"decimalPlace":null,"format":"DD/MON/YYYY","PermissibleValues":[],"ConceptualDomain":{"publicId":"2008561","version":"1","preferredName":"Occurrences","preferredDefinition":"dates, times, and durations.","longName":"OCURS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B53BD1AB-090B-398B-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-01-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2003-01-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2233081","version":"1","preferredName":"Date","preferredDefinition":"a particular day specified as the time something has, or will, happen.","longName":"C25164","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Date","conceptCode":"C25164","definition":"The particular day, month and year an event has happened or will happen.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F90B5E56-BB15-0F45-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-06-09","modifiedBy":"ONEDATA","dateModified":"2005-06-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CCR:Center for Cancer Research","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"A6545B3B-0FC3-40BF-E034-0003BA0B1A09","latestVersionIndicator":"Yes","beginDate":"2002-07-21","endDate":null,"createdBy":"JASUR","dateCreated":"2002-07-21","modifiedBy":"HARTLEYG","dateModified":"2018-06-06","changeDescription":"8/30/17 jk Transferred context, added CSI and reg status, released per Round 5 finalization task. --- Display and exchange formats are based on CTMS reporting requirements v.3.02 and all subsequent versions of these guidelines.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008601","version":"1","longName":"C3D Domain","context":"CCR","ClassificationSchemeItems":[{"publicId":"2812367","version":"1","longName":"caBIG","context":"CCR"}]},{"publicId":"2182125","version":"1","longName":"CCR Implementation","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811673","version":"1","longName":"C3D","context":"CCR"}]},{"publicId":"2183535","version":"1","longName":"Clinical Trial Mgmt Systems","context":"NCIP","ClassificationSchemeItems":[{"publicId":"2812625","version":"1","longName":"CTMS C3D Adopter Sites","context":"NCIP"},{"publicId":"2811715","version":"1","longName":"Duke University","context":"NCIP"},{"publicId":"2812724","version":"1","longName":"Duke U New CDEs","context":"NCIP"}]},{"publicId":"3886752","version":"1","longName":"For Review","context":"DCI","ClassificationSchemeItems":[{"publicId":"3891931","version":"1","longName":"For Review","context":"DCI"}]}],"AlternateNames":[{"name":"DCI","type":"USED_BY","context":"DCI"}],"ReferenceDocuments":[{"name":"Date of progression on second","type":"Preferred Question Text","description":"Date of progression on second line Bevacizumab","url":null,"context":"NCIP"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C5BB542C-1F4B-0AC1-E040-BB89AD433A0A","latestVersionIndicator":"Yes","beginDate":"2012-07-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-07-26","modifiedBy":"ZHANGWE","dateModified":"2013-09-16","changeDescription":"Curated to support Duke University clinical trial","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}